At a glance
- Originator Cortech
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatic disorders
Most Recent Events
- 29 Feb 2000 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 29 Feb 2000 Discontinued - Preclinical for Rheumatic disorders in USA (unspecified route)
- 12 Jun 1999 No-Development-Reported for Inflammation in USA (Unknown route)